Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

New research program receives DKK 100 million in funding from Novo Nordisk Foundation

The newly established research program, 'Program for Translational Hematology', has just received DKK 100 million in funding from the Novo Nordisk Foundation.

From Novo Nordisk 24 Aug 2017

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

24 Aug 2017

Study provides new insight into development of immune cells

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialized immune cell, does not depend on a growth factor called stem cell factor.

10 Aug 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

$New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod$

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.

2 Aug 2017

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects.

12 Jul 2017

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen's University in Canada to advance the preclinical development of ERYTECH's eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

12 Jul 2017

Prolonged use of cancer inhibitors can lead to severe cardiovascular problems

Plk1 inhibitors have recently been acknowledged as an "Innovative Therapy for leukaemia" by the US Food and Drug Administration.

10 Jul 2017

Timing of mutations can have effect on health and disease

A single genetic mutation can lead to completely different diseases, depending on the time and location at which the mutation occurs.

30 Jun 2017

Researchers trace origins of AML relapse to rare therapy-resistant stem cells

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

29 Jun 2017

PNNL-OHSU scientists part of NCI effort to study about role of proteins in cancer biology

The Department of Energy's Pacific Northwest National Laboratory is part of a nationwide effort to learn more about the role of proteins in cancer biology and to use that information to benefit cancer patients.

28 Jun 2017

Researchers discover how mutations in protein network drive high-risk leukemias

Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies.

14 Jun 2017

Study finds steady decline in severe health problems for childhood cancer survivors

Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.

5 Jun 2017

Investigational compound inhibits cancer-specific mutations in mice

Many malignancies develop as a result of genetic alterations in individual cells. These gene mutations often cause altered proteins that give new, growth-promoting properties to the cell.

30 May 2017

Study shows how different genetic mutations cause acute myeloid leukemia

A study led by the University of Birmingham has made a breakthrough in the understanding of how different genetic mutations cause acute myeloid leukemia.

23 May 2017

Researchers show how DPF2 protein controls blood cell production in leukemia

Many things go wrong in cells during the development of cancer. At the heart of the chaos are often genetic switches that control the production of new cells.

23 May 2017

Researchers identify new drug target for two common types of myeloid leukemia

University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of the disease.

17 May 2017

UT Health scientists discover epigenetic changes that contribute to AML

UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.

10 May 2017

FDA approves new AML drug after clinical testing at Dana-Farber

A targeted drug whose clinical testing was led by Richard Stone, MD, of Dana-Farber Cancer Institute, has become the first new treatment for newly diagnosed acute myeloid leukemia (AML) in more than 25 years.

5 May 2017

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Sarcomas- cancers of the connective tissues like muscles, joints, fat and bone - come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.

3 May 2017